PT  - JOURNAL ARTICLE
AU  - Wen, Wen
AU  - Su, Wenru
AU  - Tang, Hao
AU  - Le, Wenqing
AU  - Zhang, Xiaopeng
AU  - Zheng, Yingfeng
AU  - Liu, Xiuxing
AU  - Xie, Lihui
AU  - Li, Jianmin
AU  - Ye, Jinguo
AU  - Cui, Xiuliang
AU  - Miao, Yushan
AU  - Wang, Depeng
AU  - Dong, Jiantao
AU  - Xiao, Chuanle
AU  - Chen, Wei
AU  - Wang, Hongyang
TI  - Immune Cell Profiling of COVID-19 Patients in the recovery stage by Single-cell sequencing
AID  - 10.1101/2020.03.23.20039362
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.03.23.20039362
4099  - http://medrxiv.org/content/early/2020/03/27/2020.03.23.20039362.short
4100  - http://medrxiv.org/content/early/2020/03/27/2020.03.23.20039362.full
AB  - COVID-19 caused by SARS-CoV-2 has recently affected over 200,000 people and killed more than 8000. Immune system dysregulation such as lymphopenia and inflammatory cytokine storm has been observed in COVID-19 patients, but it remains unclear for the change of key immune cell subsets and their states during COVID-19. Here, we applied single-cell technology to comprehensively characterize transcriptional changes of peripheral blood mononuclear cells in ten patients recovered from COVID-19. Compared with healthy control, COVID-19 induced a unique signature of immune cells in humans, especially in the early recovery stage (ERS). In ERS patients, T cells were decreased remarkably, while monocytes were increased. A detailed analysis of monocytes showed that there was an increased ratio of classical CD14++ monocytes with highly inflammatory genes expression, as well as a greater abundance of CD14++IL1B+ monocytes. For nature killer (NK) cells and T cells, CD4+ T cells were significantly decreased and expressed high level of inflammatory markers, while NK cells were increased. In addition, T cells were highly expanded clone, especially in CD4+ T memory cells and CD8+ T cells. Among B cells, plasma cells were increased remarkably, and naïve B cells were reduced. Our study also identified several novel B cell receptor (BCR) changes (such as IGHV1-8 and IGHV3-7), and confirmed isotypes (IGKV3-11 and IGHV3-21) previously used for virus vaccine development. The strongest pairing frequencies, IGHV3-23+IGHJ4, indicated a monoclonal state associated with SARS-CoV-2 specificity. Furthermore, integrated analysis predicated that IL-1β and M-CSF may be novel candidate target gene for inflammatory storm, and TNFSF13, IL-18 and IL-4 may be benefit for the recovery of COVID-19 patients. Our study provides the first evidence of inflammatory immune signature in early recovery stage, suggesting that the COVID-19 patients are still vulnerable after hospital discharge. Our identification of novel BCR signaling may lead to the development of vaccine and antibodies for the treatment of COVID-19.Hight lights- The immune response sustains more than 7 days in early recovery stage of COVID-19, suggesting that the COVID-19 patients are still vulnerable after hospital discharge.- Single cell analysis revealed immune cells interaction characterized by increasing of a subset of CD14++ IL1β+ monocytes in ERS of COVID-19 patients.- Newly identified virus specific BCR changes would be helpful for the development of vaccine and antibodies against SARS-CoV-2.- IL-1β and M-CSF were discovered as novel mediators for inflammatory cytokine storm, and might be potential candidate targets in COVID-19 treatment.- TNFSF13, TNFSF13B and IL4, IL18 were discovered as novel mediators for recovery mechanisms.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialChiCTR2000030690Funding StatementThis study was supported by National Natural Science Foundation of China (Grant No. 81722034, 81670015, 81830054, 81530028, 91953122, 31871326, 81721003, 81988101),the Ministry of Science and Technology Key Program (Grant No. 2018ZX09101002, 2017ZX100203205), Shanghai Pujiang Program (Grant No. 2019PJD059),and Guangdong Natural Science Funds for Distinguished Young Scholar (Grant No. 2016A030306006, 2020B1515020057).Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Yeshttps://bigd.big.ac.cn